Teva says Dutch part of MSD's Fosamax patent revoked
Israel's Teva Pharmaceutical Industries says the Hague District Court in the Netherlands, decided to revoke the Dutch part of Merck Sharp & Dohme's (part of US drug major Merck & Co) European patent no 1,175,904, due to lack of inventive step, which relates to Fosamax (alendronate) 70mg once-weekly. This is the first European court decision on the merits of this patent, which is currently being litigated by Teva in Belgium, France, Italy, Sweden and Spain as well as in the European Patent Office.
On February 15, the Tribunal de Grande Instance de Paris, France, decided that MSD Somerset's supplementary protection certificate SPC 96C0032 covering the use of alendronate for the treatment of urolithiase and bone resorption was invalid for lack of inventive step, says Teva.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze